Drug intelligence / Profile preview

CLB-3000 (ClearB Therapeutics)

Development stage: Unknown
Lead developer: ClearB Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CLB-3000 is a therapeutic vaccine candidate being developed by ClearB Therapeutics for the treatment of chronic hepatitis B (CHB) infection. It is designed to drive a functional cure by re-educating the patient's immune system to break the tolerance associated with chronic HBV infection. The vaccine is composed of two components, CLB-405 and CLB-505, adjuvanted with Alhydrogel (aluminum hydroxide). It is administered via intramuscular injection and is currently in a Phase 1b open-label, first-in-human clinical study in Australia to evaluate its safety, tolerability, immunogenicity, and antiviral activity.

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on CLB-3000 (ClearB Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLB-3000 (ClearB Therapeutics).

Explore the full profile